BlackRock, Inc. 13D and 13G filings for Citius Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-05-08 2:22 pm Purchase |
2024-04-30 | 13G | Citius Pharmaceuticals, Inc. CTXR |
BlackRock Inc. BLK |
345,034 4.800% |
6,721 (+1.99%) |
Filing |
| 2024-01-31 2:08 pm Purchase |
2023-12-31 | 13G | Citius Pharmaceuticals, Inc. CTXR |
BlackRock Inc. BLK |
338,313 5.300% |
244,421 (+260.32%) |
Filing |
| 2022-07-08 4:56 pm Sale |
2022-06-30 | 13G | Citius Pharmaceuticals, Inc. CTXR |
BlackRock Inc. BLK |
93,892 1.600% |
-231,239 (-71.12%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Citius Pharmaceuticals, Inc. CTXR |
BlackRock Inc. BLK |
325,130 5.600% |
325,130 (New Position) |
Filing |